Waltham, Massachusetts-based TScan Therapeutics entered a collaboration agreement with Novartis to discover and develop novel T-cell Receptor (TCR)-engineered T-cell therapies for solid tumors.
Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance lead therapeutic candidates into clinical studies.
Redwood City, California-based Karius closed on a $165 million Series B round.
San Francisco-based Spruce Biosciences closed on a Series B financing round valued at $88 million, as the company develops tildacerfont for the rare genetic disorder congenital adrenal hyperplasia (CAH).
Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.
Companies continue to announce advancements in artificial intelligence programming as they harness the power of AI and machine learning to aid in drug discovery and development.
Lyra Therapeutics Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced a $29.5 million Series B equity financing.
